Department of Pharmacy, Singapore General Hospital, Singapore; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.
Department of Pharmacy, Singapore General Hospital, Singapore.
J Glob Antimicrob Resist. 2019 Jun;17:312-315. doi: 10.1016/j.jgar.2019.01.018. Epub 2019 Jan 22.
Antimicrobial stewardship programmes (ASPs) have often been recommended as a viable solution to minimise the incidence of Clostridium difficile infection (CDI), which can be life-threatening. This study aimed to evaluate whether ASP interventions have contributed to reducing CDI rates.
A retrospective review of ASP interventions issued from January 2013 to April 2014 was performed using data from the ASP database of Singapore General Hospital, a 1600-bed tertiary-care hospital in Singapore. A total of 283 interventions satisfied the inclusion criteria, of which commonly audited antibiotics were piperacillin/tazobactam (41.3%) and carbapenems (54.8%). Comparisons were made at 30days post-intervention between those with accepted or rejected interventions. The primary outcome was CDI incidence; secondary outcomes included length of hospitalisation post-intervention, 30-day mortality and CDI recurrence rate.
Whilst the median duration of antibiotic therapy was reduced by 2days (6days vs. 4 days; P<0.001), acceptance of ASP interventions did not alter primary CDI incidence at 30days (P=0.644) post-intervention. However, reduced CDI recurrence rates were observed for patients positive for CDI in the accepted patient group compared with the rejected group (0% vs. 37.5%; P=0.03), with no difference in CDI 30-day mortality between the two groups.
Intervention acceptance did not contribute to a significant reduction in CDI incidence but may be associated with lower recurrence rates, although further studies are required.
抗菌药物管理计划(ASPs)常被推荐为减少艰难梭菌感染(CDI)发生率的可行方法,因为 CDI 可能危及生命。本研究旨在评估 ASP 干预措施是否有助于降低 CDI 发生率。
对 2013 年 1 月至 2014 年 4 月期间使用新加坡综合医院 ASP 数据库的数据进行了 ASP 干预的回顾性审查,该医院是新加坡一家拥有 1600 张床位的三级保健医院。共有 283 项干预措施符合纳入标准,其中经常审核的抗生素是哌拉西林/他唑巴坦(41.3%)和碳青霉烯类(54.8%)。在干预后 30 天,比较接受或拒绝干预的患者之间的情况。主要结果是 CDI 发生率;次要结果包括干预后住院时间、30 天死亡率和 CDI 复发率。
虽然抗生素治疗的中位数持续时间缩短了 2 天(6 天与 4 天;P<0.001),但接受 ASP 干预并没有改变干预后 30 天的主要 CDI 发生率(P=0.644)。然而,在接受干预的患者中,CDI 阳性患者的 CDI 复发率较低,而在拒绝干预的患者中,CDI 复发率较高(0%与 37.5%;P=0.03),两组之间 30 天 CDI 死亡率没有差异。
干预措施的接受并没有显著降低 CDI 发生率,但可能与降低复发率有关,但还需要进一步研究。